Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 27 2025
0mins
Source: Globenewswire
Company Expansion into Cryptocurrency: Liminatus Pharma, Inc. plans to establish a subsidiary called “American BNB Strategy” to invest up to $500 million in BNB Coin, aiming for long-term growth and shareholder value while maintaining its focus on cancer therapeutics.
Strategic Investment Approach: The company emphasizes that this initiative is not speculative but based on the robust technology and potential of the BNB ecosystem, with security measures in place through an affiliated entity, Ceffu, to ensure compliance and operational integrity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
